# US 2024/0391877 A1 · Compound as inhibitor of complement factor d, and pharmaceutical composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391877 A1
- Document ID: US20240391877A1
- Status: Published application
- Kind: A1
- Application number: 18/696,975
- Filed: 2022-09-30
- Published: 2024-11-28
- Earliest claimed: 2021-09-30
- Assignees: Wuhan Createrna Science and Technology Co., Ltd.
- Applicants: Wuhan Createrna Science and Technology Co.,Ltd.
- Inventors: Jun LOU; Jingkang WU; Li LIU; Youyou SUN; Yongkai CHEN; Yihan ZHANG; Xiaoqin LU; Feng ZHOU; Ying CHEN; Liqian ZHANG; Fan YANG; Chaodong WANG
- Web page: https://patentgrep.com/patent/US20240391877A1

## CPC

- C07D 221/20: Spiro-condensed ring systems
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07D 205/12: condensed with carbocyclic rings or ring systems
- C07D 209/54: Spiro-condensed
- C07D 221/22: Bridged ring systems
- C07D 221/24: Camphidines
- C07D 265/34: condensed with carbocyclic rings
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are a compound as an inhibitor of complement factor D, and a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereof and a prodrug thereof, or a pharmaceutically acceptable salt of any one of the above-mentioned compounds, or a solvate of any one of the above-mentioned compounds. The compound has a good inhibitory activity on complement factor D, and has an excellent pharmacokinetic and pharmacodynamic activity. Formula (I)

## Claims

### Claim 1

A compound of formula (I), a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a solvate of any one of the foregoing:
wherein
R1 is H, D, C1-6 alkyl, or C1-6 alkyl substituted by 1, 2, or 3 R1-1; each R1-1 is independently halogen, —CN, —OH, C1-6 alkoxy, or —NH2;
R2 and R3 are each independently H, D, halogen, C1-6 alkyl, or C1-6 alkyl substituted by 1, 2, or 3 R2-1; each R2-1 is independently halogen, —CN, —OH, C1-6 alkoxy, or —NH2;
R4 is H or halogen; m is 0, 1, 2, or 3;
R5 and R7 are each independently H, halogen, —CN, C1-6 alkyl, or C1-6 alkoxy;
R6 is C7-12 cycloalkyl, C7-12 cycloalkyl substituted by 1, 2 or 3 R6-1, “7- to 12-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S”, or “7 to 12-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2;
R6-1 and R6-2 are each independently hydroxyl, oxo (═O), halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, or —(CH2)p—C3-6 cycloalkyl; p is 1, 2, 3, or 4;
in R6, R6-1, and R6-2, the cycloalkyl is independently a monocyclic ring, a bridged ring, or a spiro ring;
in R6, the heterocycloalkyl is a monocyclic ring, a bridged ring, or a spiro ring;
R8 is H, halogen, or C1-6 alkyl;
R9 is H, halogen, C1-6 alkyl, or C1-6 alkyl substituted by 1, 2, or 3 R9-1;
each R9-1 is independently halogen, —CN, —OH, or —NH2; n is 0, 1, 2, 3, or 4;
L is —(CRaRb)q—; q is 0, 1, 2, or 3;
Ra and Rb are each independently H, D, or halogen, or Ra and Rb are connected together to form a C3-6 cycloalkylene, and the formed cycloalkylene is a monocyclic ring, a bridged ring, or a spiro ring;
R10 is —COOH or —C(═O)ORc;
Rc is C1-6 alkyl or C1-6 alkyl substituted by 1, 2, or 3 Rc-1; each Rc-1 is independently halogen, —OH, or —C(═O)OC(CH3)3;
X is CRd or N; Rd is H, halogen, or C1-6 alkyl.

### Claim 2 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) satisfies one or more than one of the following conditions:
(1) R1 is H;
(2) R2 and R3 are each independently H, C1-3 alkyl, or C1-3 alkyl substituted by 1, 2, or 3 R2-1;
each R2-1 is independently halogen or —OH, and the halogen is preferably F;
(3) m is 0 or 1;
(4) R5 and R7 are each independently H or halogen, and the halogen is preferably F;
(5) R6 is “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2, wherein the heterocycloalkyl is a bridged ring or a spiro ring; preferably, the 8- to 11-membered heterocycloalkyl is 6-azaspiro[2.5]octyl, 5-azaspiro[2.5]octyl, 6-azaspiro[3.4]octyl, 2-azaspiro[3.4]octyl, 2-oxa-6-azaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.4]octyl, 4-oxa-7-azaspiro[2.5]octyl, 2-azaspiro[4.4]nonyl, 2-azaspiro[3.5]nonyl, 2-oxa-7-azaspiro[3.5]nonyl, 1-oxa-7-azaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 2,7-diazaspiro[3.5]nonyl, 2-oxa-8-azaspiro[4.5]decyl, 3-oxa-9-azaspiro[5.5]undecyl, 2-oxa-9-azaspiro[5.5]undecyl, 3,9-diazaspiro[5.5]undecyl, 3-azabicyclo[3.2.1]octyl, 3-azaspiro[5,5]undecyl, 8-azaspiro[4.5]decyl, or 1-oxa-6-azaspiro[3,4]octyl;
(6) each R6-2 is independently hydroxyl or C1-3 alkyl, preferably, each R6-2 is independently hydroxyl, methyl, ethyl, n-propyl, or isopropyl;
(7) R8 is H;
(8) R9 is H or halogen, and the halogen is preferably F;
(9) n is 0 or 1;
(10) q is 1;
(11) Ra and Rb are each independently H;
(12) R10 is —COOH;
(13) Rd is H.

### Claim 3 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein
R6 is “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2, wherein the heterocycloalkyl is a bridged ring or a spiro ring; preferably, R6 is “8- to 10-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8 to 10-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2.

### Claim 4 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein R1 is H;
R2 and R3 are each independently H, C1-3 alkyl, or C1-3 alkyl substituted by 1, 2, or 3 R2-1;
each R2-1 is independently halogen or —OH;
R4 is H or halogen; m is 0 or 1;
R5 and R7 are each independently H or halogen;
R6 is “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2, wherein the heterocycloalkyl is a bridged ring or a spiro ring;
each R6-2 is independently hydroxyl or C1-3 alkyl;
R8 is H;
R9 is H or halogen; n is 0 or 1;
L is —(CRaRb)q—, q is 1; Ra and Rb are each independently H;
R10 is —COOH;
X is CRd or N; Rd is H.

### Claim 5 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) satisfies one or more than one of the following conditions:
(1) in R1, R2, R3, R5, R7, R6-1, R6-2, R8, R9, Rc, and Rd, each alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl, preferably methyl or ethyl;
(2) in R1-1, R2-1, R5, R7, R6-1, and R6-2, each alkoxy is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, or tert-butoxy;
(3) in R1-1, R2, R3, R2-1, R4, R5, R7, R6-1, R6-2, R8, R9, R91, Ra, Rb, Rc-1, and Rd, each halogen is independently F, Cl, Br, or I, preferably F;
(4) in R6, each heterocycloalkyl is independently “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S”, the heterocycloalkyl is a bridged ring or a spiro ring; preferably, the heterocycloalkyl is connected to the parent through an N atom; the heterocycloalkyl is preferably

### Claim 6 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) satisfies one or more than one of the following conditions:
(1) R2 is H, R3 is H, —CH3, —CH2OH, —CH2CH2OH, —CH2F, or —CF2H;
(2) R6 is

### Claim 7 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) satisfies any one of the following conditions:
(1) R1 is H;
R2 is H, R3 is H, —CH3, or —CH2F;
R4 is H or halogen, m is 0 or 1;
R5 and R7 are each independently H or F;
R6 is “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8- to 11-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2;
each R6-2 is independently hydroxyl or C1-3 alkyl;
R8 is H;
R9 is H or F; n is 0 or 1;
L is —(CRaRb)q—; q is 1; Ra and Rb are each independently H;
R10 is —COOH;
X is CRd or N; Rd is H;
(2) R1 is H;
R2 is H, R3 is H, —CH3, or —CH2F;
R4 is H or halogen, m is 0 or 1;
R5 and R7 are each independently H or F;
R6 is “8- to 10-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” or “8- to 10-membered heterocycloalkyl with 1, 2, or 3 heteroatoms selected from 1, 2, or 3 types of N, O, and S” substituted by 1, 2, or 3 R6-2;
each R6-2 is independently hydroxyl or C1-3 alkyl;
R8 is H;
R9 is H or F; n is 0 or 1;
L is —(CRaRb)q—; q is 1; Ra and Rb are each independently H;
R10 is —COOH;
X is CRd or N; Rd is H;
(3) R1 is H;
R2 is H, R3 is H, —CH3, or —CH2F;
R4 is H or halogen, m is 0 or 1;
R5 and R7 are each independently H or F;
R6 is
or the following group substituted by 1 R6-2:
R6-2 is hydroxyl or methyl;
R8 is H;
R9 is H or F; n is 0 or 1;
L is —(CRaRb)q—; q is 1; Ra and Rb are each independently H;
R10 is —COOH;
X is CRd or N; Rd is H;
(4) R1 is H;
R2 is H, R3 is H, —CH3, or —CH2F;
R4 is H or F, m is 0 or 1;
R5 and R7 are each independently H or F;
R6 is
R8 is H;
R9 is H or F; n is 0 or 1;
L is —(CRaRb)q—; q is 1; Ra and Rb are each independently H;
R10 is —COOH;
X is CRd or N; Rd is H.

### Claim 8 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) has a structure of formula (I-1):

### Claim 9 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) has a structure of formula (I-2):

### Claim 10 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) has a structure of formula (I-3):

### Claim 11 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) has a structure of formula (I-4):
when a carbon atom marked with “” is a chiral carbon atom, it represents an R configuration, an S configuration, or a mixture thereof.

### Claim 12 (depends on 1)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1, wherein the compound of formula (I) is selected from any one of the following compounds:

### Claim 13 (depends on 12)

The compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 12, wherein the compound of formula (I) is selected from any one of the following compounds:

### Claim 14 (depends on 1)

A preparation method for a compound of formula (I), comprising the following steps:
(1) subjecting a compound of formula II-3 to a deprotection reaction to obtain a compound of formula II-4;
(2) subjecting the compound of formula II-4 to a hydrolysis reaction to obtain the compound of formula (I);
wherein R10 is —COOH, and R1, R2, R3, R4, R5, R6, R7, R8, R9, Rc, X, L, m, and n are defined as in claim 1; preferably, R1 is H.

### Claim 15 (depends on 1)

A compound of formula II-3 or formula II-4:
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, L, Rc, m, and n are defined as in claim 1; preferably, R1 is H.

### Claim 16

A compound of any one of the following:

### Claim 17 (depends on 1)

A pharmaceutical composition, comprising:
(1) the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1; and
(2) a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

A method for the treatment and/or prevention of a disease mediated by complement factor D in a subject in need thereof, comprising administering the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1; the disease mediated by complement factor D is a hematological disorder, a renal disease, a cardiovascular disease, an immunological disorder, a disease of the central nervous system, a respiratory disease, a urogenital system disease, or an ocular disorder.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease mediated by complement factor D is cold agglutinin disease, catastrophic antiphospholipid syndrome, hemolytic anemia, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, IgA nephropathy, lupus nephritis, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis (MPGN), dense-deposit disease, C3 glomerulonephritis, focal segmental glomerulosclerosis, diabetic nephropathy, systemic lupus or lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, organ transplant rejection, myasthenia gravis, Alzheimer's disease, respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, emphysema, coronavirus infection (such as SARS-CoV, MERS-CoV, or SARS-CoV-2 infection), macular degeneration, age-related macular degeneration (AMD), macular edema, diabetic macular edema, choroidal neovascularization (CNV), uveitis, Behcet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, corneal neovascularization disease, post-corneal transplant rejection, corneal dystrophy disease, autoimmune dry eye disease, Stevens-Johnson syndrome, Sjögren's syndrome, environmental dry eye disease, Fuchs' endothelial dystrophy, retinal vein occlusion, or post-operative inflammation.

### Claim 20 (depends on 1)

A method for inhibiting complement factor D inhibitor medicament in a subject in need thereof, comprising administering the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the prodrug thereof, or the pharmaceutically acceptable salt of any one of the foregoing, or the solvate of any one of the foregoing according to claim 1.
